Cancer Control. 2000;7(3) 


  • CMMI-C-040A-98, NCI-V99- 1564, CMMI-FDR001555
    Phase I/II Study of Radioimmunotherapy with Yttrium Y 90 Anti-CEA Monoclonal Antibody MN-14 With or Without Doxorubicin Plus Peripheral Blood Stem Cell Rescue in Patients With Medullary Thyroid Carcinoma

    Chairperson: Malik Juweid. Telephone: 973-844-7115. Lead organization: Garden State Cancer Center. Age range: 16 to 80.

  • CAN-OTT-9401, NCI-V94- 0566, CLB-9871
    Phase II Study of Cisplatin/Doxorubicin/Tamoxifen for Incurable Soft Tissue and Endocrine Malignancies

    Chairperson: Stan Z. Gertler. Telephone: 613-737-7700. Lead organization: Ottawa Regional Cancer Centre - Civic Campus. Age range: 65 and under.

  • Legend for Abbreviations:
    CAN-OTT = Ottawa Regional Cancer Centre CLB = Cancer & Leukemia Group B CMMI = Center for Molecular Medicine & Immunology NCI = National Cancer Institute

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER.

A searchable PDQ Web site is also accessible at


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: